|Year : 2022 | Volume
| Issue : 6 | Page : 1267-1268
Retinal ganglion cell protection by hop-flower extract as a novel neuroprotective strategy for glaucoma
Tomoko Hasegawa1, Hanako Ohashi Ikeda MD 2
1 Department of Ophthalmology and Visual Sciences, Kyoto University Graduate School of Medicine, Kyoto; Research Fellow of Japan Society for the Promotion of Science, Tokyo, Japan
2 Department of Ophthalmology and Visual Sciences, Kyoto University Graduate School of Medicine, Kyoto, Japan
|Date of Submission||30-Mar-2021|
|Date of Decision||19-May-2021|
|Date of Acceptance||06-Jul-2021|
|Date of Web Publication||12-Nov-2021|
Hanako Ohashi Ikeda
Department of Ophthalmology and Visual Sciences, Kyoto University Graduate School of Medicine, Kyoto
Source of Support: The present study was supported in part by research grants from the Ministry of Health, Labour and Welfare of Japan (to HOI), Conflict of Interest: None
|How to cite this article:|
Hasegawa T, Ikeda HO. Retinal ganglion cell protection by hop-flower extract as a novel neuroprotective strategy for glaucoma. Neural Regen Res 2022;17:1267-8
|How to cite this URL:|
Hasegawa T, Ikeda HO. Retinal ganglion cell protection by hop-flower extract as a novel neuroprotective strategy for glaucoma. Neural Regen Res [serial online] 2022 [cited 2021 Dec 8];17:1267-8. Available from: http://www.nrronline.org/text.asp?2022/17/6/1267/327344
In glaucoma, a leading cause of blindness, retinal ganglion cells are progressively damaged. Intraocular pressure reduction is the only established treatment for glaucoma (Collaborative Normal-Tension Glaucoma Study Group, 1998; Vass et al., 2007). However, in some cases, visual field loss progresses despite sufficiently reduced intraocular pressure (Collaborative Normal-Tension Glaucoma Study Group, 1998; Killer and Pircher, 2018). While intraocular pressure and age are known risk factors for glaucoma (Ernest et al., 2013), the underlying mechanisms of glaucoma progression are not fully understood. Many factors that may influence glaucoma progression, including myopia and blood flow impairment, have been investigated (Marcus et al., 2011; Ernest et al., 2013). A factor that may be related to glaucoma is the concurrent occurrence of Alzheimer’s disease, which is caused by the accumulation of amyloid β (Aβ) in the brain. Glaucomatous retinal changes in patients with Alzheimer’s disease have been reported (Wang and Mao, 2021). Other studies have reported Aβ accumulation in animal models of glaucoma with ocular hypertension (Guo et al., 2007; Ito et al., 2012). Moreover, Aβ induces apoptotic retinal ganglion cell death (Guo et al., 2007). Considering that Aβ induces retinal ganglion cell death, reducing Aβ accumulation and consequently preventing retinal ganglion cell death may be a therapeutic strategy for glaucoma [Figure 1]A.
|Figure 1: Neuroprotective effects of hop-flower extract in neurodegenerative diseases and suppression of retinal ganglion cell death by hop-flower extract in glaucoma model mice.|
(A) Schematic representation of the neuroprotective effects of hop-flower extract in neurodegenerative diseases. (B–D) Retinal ganglion cell counts in retinal flat-mount of 12-month-old GLAST (+/–): Thy1-CFP mice with or without administration of hop-flower extract: (B) Retinal ganglion cell numbers in retinal flat-mount. Retinal ganglion cell numbers were counted within 250 μm squares at a distance of 1200 μm from the disc center in four directions. *P < 0.05, Student’s t-test. (C) Representative images of retinal flat-mount. Scale bars: 500 μm. (D) Representative images of counted squares. Scale bars: 50 μm. (E, F) Optic nerve cross-sections of 18-month-old GLAST (+/–): Thy1-CFP mice with or without administration of hop-flower extract: (E) Optic nerve cross-sectional area. *P < 0.05, Student’s t-test. (F) Representative images of optic nerve cross-sections. Scale bars: 50 μm. Adapted from Hasegawa et al. (2020).
Click here to view
Effects of hop-flower extract in Alzheimer’s disease model mice: A thorough screening of more than 1600 plant extracts showed that hop-flower extract (lipid-soluble fraction) inhibits γ-secretase (Sasaoka et al., 2014). It also inhibits Aβ production in cultured cells and decreases Aβ deposition in the brain of Alzheimer’s disease model mice, in which the C-terminal fragment of the human amyloid precursor protein with the Indiana mutation (V717F) is expressed in neuronal cells (Sasaoka et al., 2014). Hop-flower extract mitigated memory impairment in Alzheimer’s model mice without deleterious side effects during lifelong administration (Sasaoka et al., 2014).
Retinal ganglion cell death prevention by hop-flower extract in glaucoma model mice: Aβ induces retinal ganglion cell death (Guo et al., 2007). Therefore, we investigated whether hop-flower extract prevents retinal ganglion cell death in glaucoma.
We used glutamate-aspartate transporter (GLAST) knockout mice as a glaucoma model (Harada et al., 2007). GLAST knockout mice, which manifest chronic retinal ganglion cell death and optic nerve degeneration without elevated intraocular pressure, have been used as glaucoma models with normal intraocular pressure. Retinal ganglion cells are damaged more severely in GLAST–/– mice than in GLAST+/– mice (Harada et al., 2007).
Administration of hop-flower extract to GLAST–/– mice was started on postnatal day 7. Retinal thickness was examined using spectral domain-optical coherence tomography (Hasegawa et al., 2020). Hop-flower extract was administered intraperitoneally from postnatal day 7 until 2 months of age and orally afterward. The ganglion cell complex, composed of the retinal nerve fiber layer, retinal ganglion cell layer, and inner plexiform layer, was thicker in 8- and 12-week-old GLAST–/– mice that received hop extract than in non-treated mice. The thickness of the outer retinal layer, composed of the outer nuclear layer, photoreceptor myoid zone, photoreceptor ellipsoid zone, and outer segment layer, did not show significant differences between mice that received hop-flower extract and non-treated mice (Hasegawa et al., 2020).
To evaluate the effect of hop-flower extract over a longer period, hop-flower extract was administered orally to GLAST+/– mice starting from 1 month of age until 18 months of age (Hasegawa et al., 2020). Mice that were orally administered the hop-flower extract had ad libitum access to water containing 1 g/L of hop-flower extract, which resulted in a daily uptake of approximately 0.2 g/kg of the extract. GLAST knockout mice were cross-bred with Thy1-CFP mice, whose retinal ganglion cells express cyan fluorescent protein (Feng et al., 2000), to generate GLAST+/–:Thy1-CFP mice. Retinal ganglion cells were imaged in vivo using a scanning laser ophthalmoscope and imaged on retinal flat-mount after enucleation. The retinal ganglion cell numbers counted with the scanning laser ophthalmoscope and the retinal flat-mount were significantly higher in 12-month-old GLAST+/– mice receiving hop-flower extract than in non-treated mice (Hasegawa et al., 2020) [Figure 1]B,[Figure 1]C,[Figure 1]D. The optic nerve was thicker in 18-month-old GLAST+/– mice that received hop-flower extract than in non-treated mice (Hasegawa et al., 2020) [Figure 1]E and [Figure 1]F. Immunostaining of the optic nerve of 18-month-old GLAST+/– mice did not show any difference in Aβ deposition between mice that received hop-flower extract and non-treated mice (Hasegawa et al., 2020).
These results show that hop-flower extract attenuated retinal ganglion cell death in a mouse model of glaucoma through mechanisms other than Aβ reduction. However, the underlying mechanisms remain to be elucidated.
Conclusion: We showed that hop-flower extract was effective against retinal ganglion cell death in a mouse model of glaucoma. Our findings may provide a potential novel therapeutic strategy for glaucoma.
The present study was supported in part by research grants from the Ministry of Health, Labour and Welfare of Japan (to HOI).
Copyright license agreement: The Copyright License Agreement has been signed by both authors before publication.
Plagiarism check: Checked twice by iThenticate.
Peer review: Externally peer reviewed.
| References|| |
Collaborative Normal-Tension Glaucoma Study Group (1998) The effectiveness of intraocular pressure reduction in the treatment of normal-tension glaucoma. Am J Ophthalmol 126:498-505.
Ernest PJ, Schouten JS, Beckers HJ, Hendrikse F, Prins MH, Webers CA (2013) An evidence-based review of prognostic factors for glaucomatous visual field progression. Ophthalmology 120:512-519.
Feng G, Mellor RH, Bernstein M, Keller-Peck C, Nguyen QT, Wallace M, Nerbonne JM, Lichtman JW, Sanes JR (2000) Imaging neuronal subsets in transgenic mice expressing multiple spectral variants of GFP. Neuron 28:41-51.
Guo L, Salt TE, Luong V, Wood N, Cheung W, Maass A, Ferrari G, Russo-Marie F, Sillito AM, Cheetham ME, Moss SE, Fitzke FW, Cordeiro MF (2007) Targeting amyloid-beta in glaucoma treatment. Proc Natl Acad Sci U S A 104:13444-13449.
Harada T, Harada C, Nakamura K, Quah HM, Okumura A, Namekata K, Saeki T, Aihara M, Yoshida H, Mitani A, Tanaka K (2007) The potential role of glutamate transporters in the pathogenesis of normal tension glaucoma. J Clin Invest 117:1763-1770.
Hasegawa T, Ikeda HO, Iwai S, Sasaoka N, Kakizuka A, Tsujikawa A (2020) Hop flower extracts mitigate retinal ganglion cell degeneration in a glaucoma mouse model. Sci Rep 10:21653.
Ito Y, Shimazawa M, Tsuruma K, Mayama C, Ishii K, Onoe H, Aihara M, Araie M, Hara H (2012) Induction of amyloid-β(1-42) in the retina and optic nerve head of chronic ocular hypertensive monkeys. Mol Vis 18:2647-2657.
Killer HE, Pircher A (2018) Normal tension glaucoma: review of current understanding and mechanisms of the pathogenesis. Eye 32:924-930.
Marcus MW, de Vries MM, Junoy Montolio FG, Jansonius NM (2011) Myopia as a risk factor for open-angle glaucoma: a systematic review and meta-analysis. Ophthalmology 118:1989-1994.
Sasaoka N, Sakamoto M, Kanemori S, Kan M, Tsukano C, Takemoto Y, Kakizuka A (2014) Long-term oral administration of hop flower extracts mitigates Alzheimer phenotypes in mice. PLoS One 9:e87185.
Vass C, Hirn C, Sycha T, Findl O, Bauer P, Schmetterer L (2007) Medical interventions for primary open angle glaucoma and ocular hypertension. Cochrane Database Syst Rev doi: 10.1002/14651858.CD003167.pub3.
Wang L, Mao X (2021) Role of retinal amyloid-β in neurodegenerative diseases: overlapping mechanisms and emerging clinical applications. Int J Mol Sci 22:2360.
C-Editors: Zhao M, Liu WJ, Qiu Y; T-Editor: Jia Y